The primary endpoint will be the seroprotection rate which is defined as the proportion of subjects with HAI titer ≥ 1:40. The other immunogenicity endpoints include seroconversion rate and geometric mean folds increase in HAI titer.
The secondary endpoint is to evaluate the safety and tolerability profiles including the presence or absence of the pre-specified reactogenicity events and other serious/non-serious adverse events of the AdimFlu-S.
18 Years and older (Adult, Senior)
January 23, 2012
December 28, 2012
National Taiwan University Hospital Taipei, Taiwan
† Study has passed its completion date and status has not been verified in more than two years.